Please login to the form below
Orfadin
This page shows the latest Orfadin news and features for those working in and with pharma, biotech and healthcare.
Orphan drug firm Sobi opens new European base
In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1). ... More recently the FDA this week began its review
Latest news
-
Sobi wins European approval for oral form of orphan drug Orfadin
Expandstreatment options for rare genetic disease HT-1. . The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone). ... An oral suspension of Orfadin for paediatric use will
-
PatientsLikeMe takes aim at one of world's rarest diseases
disease. Although there is currently no cure for AKU, Swedish Orphan Biovitrum's tyrosinaemia treatment Orfadin (nitisinone) is used off-label to treat AKU and is expected to enter phase III
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Content Editor - Biotechnology
-
Salary TBC
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
